Denali Therapeutics Inc. Payments of Financing Costs
Denali Therapeutics Inc. (DNLI) reported Payments of Financing Costs of $324.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2026-02-26
- Denali Therapeutics Inc. payments of financing costs for fiscal 2025 was $324.00K.
- Denali Therapeutics Inc. payments of financing costs for fiscal 2024 was $0.00.
- Denali Therapeutics Inc. payments of financing costs for fiscal 2023 was $0.00.
| Period end | Payments of Financing Costs 12 month |
|---|---|
| 2025-12-31 | $324.00K 10-K · filed 2026-02-26 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |